Patents by Inventor Alf D. Larsen

Alf D. Larsen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5589456
    Abstract: Mammalian granulocyte-colony stimulating factor (G-CSF) receptor proteins, DNAs and expression vectors encoding mammalian G-CSF receptors, and processes for producing mammalian G-CSF receptors as products of recombinant cell culture, are disclosed.
    Type: Grant
    Filed: February 2, 1995
    Date of Patent: December 31, 1996
    Assignee: Immunex Corporation
    Inventors: Craig A. Smith, Alf D. Larsen, John E. Sims, Benson M. Curtis
  • Patent number: 5422248
    Abstract: Mammalian granulocyte-colony stimulating factor (G-CSF) receptor proteins, DNAs and expression vectors encoding mammalian G-CSF receptors, and processes for producing mammalian G-CSF receptors as products of recombinant cell culture, are disclosed.
    Type: Grant
    Filed: January 15, 1993
    Date of Patent: June 6, 1995
    Assignee: Immunex Corporation
    Inventors: Craig A. Smith, Alf D. Larsen, John E. Sims, Benson M. Curtis
  • Patent number: 5317087
    Abstract: Interleukin-2 receptor derived from normal and malignant cells has been purified by use of various techniques including affinity chromatography in conjunction with a monoclonal antibody directed to the receptor. The purification process also includes reversed phased high performance liquid chromatography. By these techniques, interleukin-2 receptor has been purified to homogeneity. The high purification of the interleukin-2 receptor has made possible the sequencing of the amino acid residues at the N-terminal of this protein molecule. Double-stranded cDNA is prepared from polyadenylated RNA extracted from cell lines or other sources known to produce IL-2 receptor. The cDNA is inserted within a plasmid vector and then the recombinant plasmid employed to transform an appropriate host. Transformed hosts are identified and grouped into pools.
    Type: Grant
    Filed: October 22, 1990
    Date of Patent: May 31, 1994
    Assignee: Immunex Corporation
    Inventors: Douglas P. Cerretti, Cosman, Steven K. Dower, Carl J. March, David L. Urdal, Alf D. Larsen
  • Patent number: 5122459
    Abstract: Double-stranded cDNA is prepared from polyadenylated RNA extracted from activated human peripheral blood adherent mononuclear cells. The cDNA is inserted within a plasmid vector and then the recombinant plasmid employed to transform an appropriate host. Transformed hosts are identified and grouped into pools. Plasmid DNA prepared from these pools is hybridized with a labeled, synthetic oligonucleotide probe corresponding to a portion of the amino acid sequence of the interleukin 1 protein. Pools of host cells that provide a positive signal to the probe are identified, plated out and then employed in direct bacterial colony hybridization with the same probe, thereby to isolate the particular positive colony. Plasmid DNA is prepared from this colony and characterized by restriction enzyme mapping and sequencing by chain-termination method. The coding region for the IL-1 gene is inserted into a shuttle vector for amplification of the vector followed by expression of functional IL-1.
    Type: Grant
    Filed: November 30, 1989
    Date of Patent: June 16, 1992
    Assignee: Immunex Corporation
    Inventors: Paul J. Conlon, III, David j. Cosman, Kenneth H. Grabstein, Thomas P. Hopp, Shirley R. Kronheim, Alf D. Larsen, Carl J. March, Virginia L. Price, Douglas P. Cerretti
  • Patent number: 5006465
    Abstract: A process for preparing bovine interleukin-2 (bIL-2) by culturing a microbial host transformed by a vector containing a DNA sequence encoding bIL-2 under conditions suitable for the expression of bIL-2 and recovering bIL-2.
    Type: Grant
    Filed: August 11, 1989
    Date of Patent: April 9, 1991
    Inventors: Dirk M. Anderson, Paul E. Baker, Michael A. Cantrell, Douglas P. Cerretti, David J. Cosman, Steven D. Gimpel, Kenneth H. Grabstein, Alf D. Larsen, Kate N. McKereghan
  • Patent number: 4882282
    Abstract: A chemically-synthesized oligonucleotide composing a portion of the nucleotide sequence of the human IL-2 is employed as a probe to isolate the gene coding for human IL-2. The human IL-2 gene is selected from a cDNA library prepared from RNA produced by mitogen-stimulated Jurkat cells. Double-stranded cDNA is prepared from polyadenylated RNA extracted from bovine cells thought to produce interleukin-2. Such cDNA is inserted within a plasmid vector and the recombinant plasmid employed to transform hosts. Plasmid DNA, prepared from pools of the transformed hosts, is hybridized with a probe composed of a large portion of the coding sequence of the human IL-2 gene. Pools of host cells that provide signal to the human cDNA probe are identified, subdivided, and rescreened until a single positive colony is identified. Bovine plasmid cDNA is prepared from this colony, and the bIL-2 gene is sequenced.
    Type: Grant
    Filed: July 31, 1986
    Date of Patent: November 21, 1989
    Assignee: Immunex Corporation
    Inventors: Dirk M. Anderson, Paul E. Baker, Michael A. Cantrell, Douglas P. Cerretti, David J. Cosman, Steven D. Gimpel, Kenneth H. Grabstein, Alf D. Larsen, Kate N. McKereghan